Kyntra Bio reports $12 million Q2 2026 net income
Kyntra Bio reports $12 million in net income for Q2 2026, versus a $13.7 million net loss a year earlier, while FG3246, FG3180 and roxadustat programs advance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.